SNYNF
What one share of Sanofi holds
Pharmaceutical Preparations
We apply our deep understanding of the immune system to invent medicines and vaccines that positively impact millions of
Sanofi’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Profit | $3.60 |
|---|---|
| Cash and investments | $3.68 |
| Debt | $9.00 |
| Book value | $34.35 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | $2.01 | — | $3.35 | — | $23.60 |
| 2017 | — | $3.75 | — | $3.29 | — | $27.84 |
| 2018 | — | $2.03 | — | $2.61 | — | $27.08 |
| 2019 | — | $1.23 | — | $3.44 | — | $26.44 |
| 2020 | — | $5.57 | — | $3.36 | — | $30.85 |
| 2021 | — | $2.93 | — | $4.95 | — | $30.76 |
| 2022 | — | $3.51 | — | $4.41 | — | $31.73 |
| 2023 | — | $2.32 | — | $4.42 | — | $32.38 |
| 2024 | — | $2.39 | — | $3.91 | — | $31.76 |
| 2025 | — | $3.60 | — | $4.96 | — | $34.35 |